Faye Flemming, RN, BSN, OCN, is the Oncology Service Line Director at Southside Regional Medical Center (SRMC) in Petersburg, VA. In this capacity she is responsible for oversight and strategic planning of all oncology-related services, departments and programs. Working closely with all hospital departments, physicians, managers, patients and the community Faye’s major roles include: assessing oncology needs; strategic planning; oncology service line growth and development; oncology staff and patient education; community outreach; & quality of our oncology program and care.
Ms. Flemming has held OCN certification for the last 29 years. She has 40 years of oncology experience including more than30 years of oncology management. Faye has worked in various hospital, clinic and outpatient settings in the U.S. and Egypt utilizing her management and oncology expertise in: service line development, consulting, project management, coaching of healthcare professionals, team building, strategic planning, education, quality improvement, marketing, customer service, community outreach, program development, and conference planning.
Ariel Foster has served as a Patient Financial Advocate for more three years at the St. Luke’s Mountain States Tumor Institute (MSTI) Clinic in Fruitland, Idaho. She has worked in the advocacy field in various capacities since 2005. Ms. Foster realized her passion for healthcare advocacy when her aunt was diagnosed with Thyroid Cancer that had metastasized to the liver. She is extremely grateful to be a part of the wonderful clinicians and caregivers at St. Luke’s, as well as help patients who have complex financial concerns feel more at ease with their treatment.
Ms. Foster has served as a panelist and presenter for ACCC, as well as serving on the Financial Advocacy Network Advisory Committee.
She graduated from the College of Idaho with a degree in Anthropology and Sociology.
Michael Reff, RPh, MBA, is the Founder and Executive Director of the National Community Oncology Dispensing Association, Inc. (NCODA). NCODA is the first patient-centered organization dedicated to shaping the value proposition for medically integrated oncology practices. NCODA supports a membership of over 2,000 healthcare practitioners employed at over 500 practice settings. Previously, Michael established The Patient Rx Center at Hematology/Oncology Associates of Central New York, a medically integrated oncology pharmacy service focused on positive patient experiences with oral oncolytics.
Michael serves on the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative Steering Committee. He also served on the Association of Community Cancer Centers' Editorial Board, Governmental Affairs Committee, the Advisory Committee for ACCC's Improving Quality Care in Renal Cell Carcinoma education program, and Dispensing Pharmacy Project Committee. He shares his passion for patients through delivering presentations and publishing articles addressing the importance of the continuity of care for oral oncolytics. Michael has extensive pharmaceutical industry experience, spanning many disciplines including oncology research, corporate compliance, international supply chain and biologics manufacturing.
Marc Smaldone, MD, MSHP, FACS is a urologic oncologist specializing in the surgical management of tumors of the kidney, bladder, prostate, adrenal, testis and other genitourinary and an associate professor in the department of surgical oncology at Fox Chase Cancer Center in Philadelphia, Pennsylvania. He is a panel member of NCCN, Prostate Cancer Early Detection. His research interests focus on quality improvement, performance measurement, and improving care coordination at the time of regionalization for complex oncologic care.
Dr. Smaldone earned his master's of health policy research at the University of Pennsylvania and completed his medical training at the State University of New York at Stony Brook. He earned his residency in urologic surgery at the University of Pittsburgh in Pennsylvania and completed his fellowship in urologic oncology at Fox Chase Cancer Center in Philadelphia.
Financial support provided by Pfizer Oncology.